GNKG 168
Alternative Names: CpG 685; CpG ODN; GNKG168Latest Information Update: 02 Oct 2021
At a glance
- Originator Changchun Huapu Biotechnology
- Developer SBI Biotech
- Class Antineoplastics; Nucleic acids; Oligonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 28 Oct 2015 Discontinued - Phase-I for Chronic lymphocytic leukaemia in USA (IV)
- 10 Jan 2015 No development reported - Phase-I for Chronic lymphocytic leukaemia in USA (IV)
- 30 Sep 2011 Phase-I development is ongoing in USA (NCT01035216)